Skip to site menu Skip to page content

Molex to acquire drug device company Vectura

Vectura will strengthen Phillips Medisize's capabilities with its specialised inhalation expertise.

RanjithKumar Dharma September 18 2024

Molex has entered an agreement to acquire UK-based inhalation drug device design and formulation company Vectura Group, via its affiliate Molex Asia Holdings.

This acquisition from Vectura Fertin Pharma, a subsidiary of Philip Morris International, is expected to enhance the capabilities of Phillips Medisize, a Molex company, by bringing in specialised inhalation expertise.

Phillips Medisize president Paul Chaffin said: “Combining the strengths of Phillips Medisize and Vectura will enhance our ability to deliver a broader portfolio of inhalation combination drug devices and solutions to our pharmaceutical customers and support our mission to help people live healthier, more productive lives.”

Vectura is involved in the formulation and device development of dry powder inhalers (DPI), pressurised metered-dose inhalers (pMDI), and nasal and nebuliser products for biologics, small molecules, complex combinations, and generic products.

The acquisition also encompasses Vectura's services in pharmaceutical analysis, process development, technical transfer, clinical trial supplies, and regulatory services.

Molex CEO Joe Nelligan said: “The acquisition of Vectura is the latest step in building an industry-leading capability in medical.

“It also demonstrates Molex’s commitment to acquiring opportunities to better serve market needs across our portfolio.”

The transaction is expected to be finalised by the end of 2024, following receipt of regulatory approvals and the fulfilment of other customary closing conditions.

In November 2023, Molex announced the opening of a new 23,000m² facility in Poland, aimed at significantly boosting Phillips Medisize's medical device production capacity.

Molex acquired Phillips Medisize in 2016 to grow its healthcare business at scale.

Phillips Medisize is involved in designing, engineering and manufacturing products for the pharmaceutical and wider healthcare industry.

It has over 6,000 employees and collaborates with customers at 29 sites spread across North America, Europe and Asia.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close